Fintel reports that on October 31, 2025, Baird maintained coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a Outperform recommendation. Analyst Price Forecast Suggests 80.35% Upside As of ...
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.
Gallup’s latest health index links the rapid rise of semaglutide and similar injectables to measurable population-level weight loss.
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...
The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...
Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for ...
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) ...
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil ...
While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in ...
Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback